Clinical trials: Skin and Soft Tissue Infection
Soft Tissue Infections
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP for 7-14 days) in patients with cSSSI due to…
- Trial name
- NCT00426933
- Testing
- Daptomycin, Vancomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Skin Infections, Streptococcal Infections
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
The purpose of this study is to characterize the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole after a single…
- Trial name
- NCT01030731
- Testing
- Ceftobiprole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Sarcoma, Kaposi, HIV Infections
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00005931
- Testing
- SU5416
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
- Trial name
- NCT00087490
- Testing
- linezolid, vancomycin
- Where
- 126 sites in United States, Argentina and 14 more
- Volunteers
- 1,077 people
- Sponsor
- Pfizer
Bacterial Infections
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.
- Trial name
- NCT00998309
- Testing
- Azithromycin SR
- Volunteers
- 502 people
- Sponsor
- Pfizer
Bacteremia, Soft Tissue Infections
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection…
- Conditions
- Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
- Trial name
- NCT03643952
- Testing
- Daptomycin for Injection
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Complicated Skin and Soft Tissue Infection
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
- Trial name
- NCT01499277
- Testing
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Where
- 91 sites in United States, Argentina and 26 more
- Volunteers
- 802 people
- Sponsor
- Pfizer
Staphylococcus (S.) Aureus Infection
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
- Trial name
- LTBSA701 (NCT06719219)
- Testing
- LTB-SA7
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Superficial Skin and Soft Tissue Infections Caused by Gram-positive Bacteria
A Phase I Clinical Trial to Evaluate CMS-F021 Following Single and Multiple Doses in Healthy Participants
"This study is a first-in-human (FIH) trial of CMS-F021 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07790770
- Testing
- CMS-F021 Gel, Drug: CMS-F021 Gel healthy participant
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dermavon Holdings Limited
Sarcoma, Kaposi, HIV Infections
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
- Conditions
- Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
- Trial name
- NCT00002153
- Testing
- A-007
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- DEKK-TEC, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Skin Structures and Soft Tissue Infections
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
- Trial name
- REVIVE-1 (NCT02600611)
- Testing
- iclaprim, vancomycin
- Where
- 56 sites in United States, Bulgaria and 8 more
- Volunteers
- 600 people
- Sponsor
- Motif Bio
Sarcoma, Kaposi, HIV Infections
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).
- Trial name
- NCT00002185
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Agouron Pharmaceuticals
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene